10-KPeriod: FY2009

MCKESSON CORP Annual Report, Year Ended Mar 31, 2009

Filed May 5, 2009For Securities:MCK

Summary

McKesson Corporation's 2009 Form 10-K report, filed May 4, 2009, covers the fiscal year ending March 30, 2009. The filing indicates McKesson is a large accelerated filer, with a substantial market capitalization of approximately $14.5 billion in September 2008. This report provides a comprehensive overview of the company's business operations, financial performance, risk factors, and management's discussion of results and financial condition. Investors should pay close attention to the detailed business segments, potential risks that could impact future performance, and the financial data presented. The report also incorporates by reference portions of the company's 2009 Proxy Statement, which will likely contain important information regarding corporate governance, executive compensation, and security ownership. The extensive table of contents suggests a thorough review of McKesson's operational and financial landscape for the period.

Financial Highlights

54 data points
Beta

Revenue

$106.63B

5.0% Gross Margin

Net Income

$823.00M

0.8% Net Margin

EPS (Diluted)

$2.95

Total Assets

$25.27B

Cash & Equivalents

$2.11B

Free Cash Flow

$1.16B

Financial Statements
Beta
Revenue$106.63B
Cost of Revenue$101.25B
Gross Profit$5.38B
R&D Expenses$364.00M
Operating Expenses$4.18B
Operating Income$1.20B
Net Income$823.00M
EPS (Basic)$2.99
EPS (Diluted)$2.95
Shares Outstanding (Basic)275.00M
Shares Outstanding (Diluted)279.00M

Key Highlights

  • 1McKesson Corporation is classified as a large accelerated filer, indicating a significant market presence and adherence to stringent SEC reporting requirements.
  • 2The company's market capitalization, as of September 2008, was approximately $14.5 billion, signifying a substantial enterprise value for investors.
  • 3The report details the company's business segments, providing insight into its diverse revenue streams and operational focus.
  • 4Risk factors are explicitly addressed, offering investors a clear understanding of potential challenges and uncertainties facing the company.
  • 5Management's Discussion and Analysis (MD&A) offers crucial context on financial condition and operational results, enabling investors to assess performance trends.
  • 6The incorporation by reference of the 2009 Proxy Statement suggests key information on corporate governance, executive compensation, and shareholder matters will be available.
  • 7The filing covers a broad range of disclosures, from legal proceedings and properties to controls and procedures, aiming to provide a holistic view of the company's standing.

Frequently Asked Questions

While the specific business segments are detailed within the report (Part I, Item 1), McKesson is broadly known as a global leader in healthcare services, providing pharmaceutical distribution, technology solutions, and health and well-being products. Investors should review the 'Business' section for granular details on its operational segments and strategies.

The 'Risk Factors' section (Part I, Item 1A) is crucial for understanding potential challenges. These could include regulatory changes, competition, reliance on key suppliers or customers, operational disruptions, and macroeconomic factors. Investors should thoroughly review this section for a comprehensive understanding of potential headwinds.

Key sections for financial analysis include 'Selected Financial Data' (Part II, Item 6), 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (Part II, Item 7), and the 'Financial Statements and Supplementary Data' (Part II, Item 8). These sections provide historical financial performance, management's insights, and the audited financial statements.

Information incorporated by reference from the 2009 Proxy Statement typically includes details on directors, executive officers, corporate governance, executive compensation, and security ownership by management and major shareholders. Investors interested in these aspects should consult the referenced Proxy Statement.